{"id":582266,"date":"2022-01-17T11:46:01","date_gmt":"2022-01-17T11:46:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=582266"},"modified":"2022-01-17T11:46:01","modified_gmt":"2022-01-17T11:46:01","slug":"scleroderma-market-size-epidemiology-treatment-leading-companies-drugs-and-competitive-analysis-by-delveinsight-boehringer-ingelheim-corbus-pharmaceuticals-bayer-and-more","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/scleroderma-market-size-epidemiology-treatment-leading-companies-drugs-and-competitive-analysis-by-delveinsight-boehringer-ingelheim-corbus-pharmaceuticals-bayer-and-more_582266.html","title":{"rendered":"Scleroderma Market Size, Epidemiology, Treatment, Leading Companies, Drugs And Competitive Analysis By DelveInsight | Boehringer Ingelheim, Corbus Pharmaceuticals, Bayer, And More"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1642314840.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Scleroderma Market Size, Epidemiology, Treatment, Leading Companies, Drugs And Competitive Analysis By DelveInsight | Boehringer Ingelheim, Corbus Pharmaceuticals, Bayer, And More\" src=\"https:\/\/www.abnewswire.com\/uploads\/1642314840.jpeg\" alt=\"Scleroderma Market Size, Epidemiology, Treatment, Leading Companies, Drugs And Competitive Analysis By DelveInsight | Boehringer Ingelheim, Corbus Pharmaceuticals, Bayer, And More\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Scleroderma Treatment Market<\/div>\n<\/div>\n<\/div>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s &rdquo;&nbsp;<strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/scleroderma-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Scleroderma Market<\/a>&nbsp;Insights, Epidemiology, and Market Forecast-2030<\/strong>&Prime;&nbsp;report delivers an in-depth understanding of the Scleroderma, historical and forecasted epidemiology as well as the Scleroderma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some facts of&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/scleroderma-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Scleroderma Market<\/a>:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>In the United States, the prevalence of scleroderma is 240 per million and an annual incidence of 19 per million.<\/li>\n<li>In Europe, the prevalence of scleroderma is estimated to be between 10 and 150 per million people, while the annual incidence has been reported to be between 3 and 28 per million people.<\/li>\n<li>Women are four times more prone to develop systemic scleroderma than men.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Scope of&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/scleroderma-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Scleroderma Market Reports<\/a>:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The report covers the descriptive overview of Scleroderma, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies<\/li>\n<li>Comprehensive insight has been provided into the Scleroderma epidemiology and treatment in the 7MM<\/li>\n<li>Additionally, an all-inclusive account of both the current and emerging therapies for Scleroderma are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape<\/li>\n<li>A detailed review of Scleroderma market; historical and forecasted is included in the report, covering drug outreach in the 7MM<\/li>\n<li>The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Scleroderma market<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Free Sample Report:&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/scleroderma-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/scleroderma-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Scleroderma<\/strong>, or systemic sclerosis, is a chronic connective tissue disease generally classified as one of the autoimmune rheumatic diseases. It causes tissue throughout the body, including the lungs and other organs, to thicken and scar. SSc-ILD is a progressive lung disease in which lung function declines over time, and it can be debilitating and life-threatening. ILD is the leading cause of death among people with scleroderma, typically resulting from a loss of pulmonary function that occurs when the lungs cannot supply enough oxygen to the heart. Scleroderma is majorly of two types: localized scleroderma and systemic sclerosis (SSc).<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of Scleroderma Companies:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Boehringer Ingelheim International GmbH<\/li>\n<li>Corbus Pharmaceuticals Holdings, Inc.<\/li>\n<li>Bayer AG<\/li>\n<li>Gilead Sciences, Inc.<\/li>\n<li>Allergan, Inc.<\/li>\n<li>Pfizer, Inc.<\/li>\n<li>Sanofi<\/li>\n<li>GlaxoSmithKline plc<\/li>\n<li>Cumberland Pharmaceuticals, Inc.<\/li>\n<li>Actelion Pharmaceuticals, Inc.<\/li>\n<li>And Many Others<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Free Sample Report:&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/scleroderma-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/scleroderma-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents:<\/strong><\/p>\n<ol style=\"text-align: justify;\" start=\"1\">\n<li>Key Insights<\/li>\n<li>Executive Summary of Scleroderma<\/li>\n<li>Competitive Intelligence Analysis for Scleroderma<\/li>\n<li>Scleroderma: Market Overview at a Glance<\/li>\n<li>Scleroderma: Disease Background and Overview<\/li>\n<li>Patient Journey<\/li>\n<li>Scleroderma Epidemiology and Patient Population<\/li>\n<li>Treatment Algorithm, Current Treatment, and Medical Practices<\/li>\n<li>Unmet Needs<\/li>\n<li>Key Endpoints of Scleroderma Treatment<\/li>\n<li>Marketed Products<\/li>\n<li>Emerging Therapies<\/li>\n<li>Scleroderma: Seven Major Market Analysis<\/li>\n<li>Attribute analysis<\/li>\n<li>7MM: Market Outlook<\/li>\n<li>Access and Reimbursement Overview of Scleroderma<\/li>\n<li>KOL Views<\/li>\n<li>Market Drivers<\/li>\n<li>Market Barriers<\/li>\n<li>Appendix<\/li>\n<li>DelveInsight Capabilities<\/li>\n<li>Disclaimer<\/li>\n<li>About DelveInsight<\/li>\n<\/ol>\n<p style=\"text-align: justify;\">DelveInsght&rsquo;s&nbsp;Competitive Intelligence Service&nbsp;includes a multidimensional coverage, helping to keep track of competitors and gain traction in the dynamic market by overcoming the challenges and expediting business growth through a strategic and tactical approach.<\/p>\n<p style=\"text-align: justify;\"><strong>About&nbsp;DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a premier Business Consulting and Market Research firm focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical and Bio-Tech companies formulate prudent business decisions.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56434.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Ankit Nigam<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=scleroderma-market-size-epidemiology-treatment-leading-companies-drugs-and-competitive-analysis-by-delveinsight-boehringer-ingelheim-corbus-pharmaceuticals-bayer-and-more\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +19193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/scleroderma-market\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/report-store\/scleroderma-market<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/report-store\/scleroderma-market\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=scleroderma-market-size-epidemiology-treatment-leading-companies-drugs-and-competitive-analysis-by-delveinsight-boehringer-ingelheim-corbus-pharmaceuticals-bayer-and-more\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Scleroderma Treatment Market DelveInsight&rsquo;s &rdquo;&nbsp;Scleroderma Market&nbsp;Insights, Epidemiology, and Market Forecast-2030&Prime;&nbsp;report delivers an in-depth understanding of the Scleroderma, historical and forecasted epidemiology as well as the Scleroderma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/scleroderma-market-size-epidemiology-treatment-leading-companies-drugs-and-competitive-analysis-by-delveinsight-boehringer-ingelheim-corbus-pharmaceuticals-bayer-and-more_582266.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,423],"tags":[],"class_list":["post-582266","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/582266","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=582266"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/582266\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=582266"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=582266"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=582266"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}